Sex: F
Vaccine: MNQ, RAB, YF, MNQ, RAB, YF
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling, Wrong technique in product usage process
Clinical narrative: Menactra and YF-Vax administered on the same day in the same site as RabAvert; Redness; Swelling; Itchiness around injection site; Injection site erythema; injection site swelling; Case reference number US-BN-2022-000225, initially downloaded from Vaccine Adverse Event Reporting System (VAERS) on 07-Mar-2022, is a spontaneous case received from other health professional via health authority VAERS (Worldwide Unique Identifier 2119699-1) and concerns a 28-year-old female patient.  The patient's medical history and concomitant medication details were not provided.  On 10-Feb-2022, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus vaccine, batch number: ARBA911D), at an unknown dose, administered intramuscularly in the left arm and for unknown indication, with co-suspects Menactra (meningococcal vaccine, batch number: U7207AA) administered intramuscularly and YF-Vax (yellow fever vaccine, batch number: UJ397AA) administered subcutaneously, both at an unknown dose, administered in the left arm and for unknown indication (explicitly coded as 'Vaccination error').  On 11-Feb-2022, one day after the first dose, the patient experienced redness, swelling, itchiness around the injection site, injection site erythema and injection site swelling.  At the time of this report, the patient was recovering from the events of 'redness', 'swelling', 'injection site erythema', 'injection site swelling' and 'injection site itching', reported as improving and only mildly itchy.  The reporter assessed all the events as non-serious. Causality assessment was not provided.   No further information was provided.; Reporter's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.; Sender's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.